Nov 19, 2010 · VTD resulted in significantly longer TTP and PFS in patients relapsing after ASCT. Analysis of response and safety data are on going and results ...
VTD resulted in significantly longer TTP and PFS in patients relapsing after ASCT. Analysis of response and safety data are on going and results will be ...
People also ask
What is the difference between Velcade and bortezomib?
Why is dexamethasone given with bortezomib?
What does Velcade do for multiple myeloma?
What is bortezomib thalidomide dexamethasone regimen?
... (thalidomide dexamethasone) in disease progressing or relapsing after asct ... autologous stem cell transplantation improves outcome in multiple myeloma patients ...
Bortezomib (Velcade (R))-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing ...
Bortezomib (Velcade)-Thalidomide-Dexaemthasone (VTD) is superior ... patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation ...
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation ... Progressing after ...
Missing: superior | Show results with:superior
... thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized ...
Jul 31, 2020 · ... bortezomib and dexamethasone for patients with ... multiple myeloma relapsing/progressing after autologous stem cell transplantation.
Apr 16, 2019 · ... thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 ...
Mar 2, 2011 · mide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT).